General principles of tumor immunotherapy Basic and Clinical Applications of Tumor Immunology /

Por Kaufman, Howard L., Wolchok, Jedd D.
Publicado em 2007

Immune system versus tumor: shifting the balance in favor of DCs and effective immunity

Por Kaufman, Howard L., Disis, Mary L.
Publicado em 2004

Molecular targeting in oncology

Por Kaufman, Howard L., Wadler, Scott., Antman, Karen.
Publicado em 2008

An update on TroVax(®) for the treatment of progressive castration-resistant prostate cancer

Por Abern, Michael, Kaufman, Howard L, Latchamsetty, Kalyan
Publicado em 2011

Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood

Por Zhang, Fan, Kaufman, Howard L, Deng, Youping, Drabier, Renee
Publicado em 2013

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Por Kaufman, Howard L, Ruby, Carl E, Hughes, Tasha, Slingluff, Craig L
Publicado em 2014

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Por Rehman, Hasan, Silk, Ann W., Kane, Michael P., Kaufman, Howard L.
Publicado no J Immunother Cancer (2016)

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma

Por Hughes, Tasha, Coffin, Robert S, Lilley, Caroline E, Ponce, Rafael, Kaufman, Howard L
Publicado no Oncolytic Virother (2014)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

Por Zloza, Andrew, Broucek, Joseph R, Huelsmann, Erica J, Hughes, Tasha, Kaufman, Howard L
Publicado em 2013

High-Dose IL-2 Induces Rapid Albumin Uptake by Endothelial Cells Through Src-Dependent Caveolae-Mediated Endocytosis

Por Zloza, Andrew, Kim, Dae Won, Broucek, Joseph, Schenkel, Jason M., Kaufman, Howard L.
Publicado em 2014

The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma

Por Hughes, Tasha, Klairmont, Matthew, Broucek, Joseph, Iodice, Gail, Basu, Sanjib, Kaufman, Howard L.
Publicado no Cancer Immunol Immunother (2015)

Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment

Por Kim-Schulze, Seunghee, Kim, Hong Sung, Fan, Qing, Kim, Dae Won, Kaufman, Howard L
Publicado em 2008

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Por Batus, Marta, Waheed, Salman, Ruby, Carl, Petersen, Lindsay, Bines, Steven D., Kaufman, Howard L.
Publicado em 2013

Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies

Por Bereta, Michal, Hayhurst, Andrew, Gajda, Mariusz, Chorobik, Paulina, Targosz, Marta, Marcinkiewicz, Janusz, Kaufman, Howard L.
Publicado em 2007

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an...

Por Shafren, Darren, Quah, Min, Wong, Yvonne, Andtbacka, Robert HI, Kaufman, Howard L, Au, Gough G
Publicado no J Immunother Cancer (2014)

Cancer immunotherapy trials: leading a paradigm shift in drug development

Por Emens, Leisha A., Butterfield, Lisa H., Hodi, F. Stephen, Marincola, Francesco M., Kaufman, Howard L.
Publicado no J Immunother Cancer (2016)

Combination immunotherapy: a road map

Por Ott, Patrick A., Hodi, F. Stephen, Kaufman, Howard L., Wigginton, Jon M., Wolchok, Jedd D.
Publicado no J Immunother Cancer (2017)

4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines

Por Kudo-Saito, Chie, Hodge, James W., Kwak, Heesun, Kim-Schulze, Seunghee, Schlom, Jeffrey, Kaufman, Howard L.
Publicado em 2006

The contralateral sentinel node

Por Komenaka, Ian K., Nguyen, Eric T., DeRaffele, Gail, Mitcham, Josephine, Hurst-Wicker, Karl S., Kaufman, Howard L.
Publicado em 2005

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2

Por Kaufman, Howard L, Aung, Sandra, Morse, Michael, Wong, Michael, Lowder, James, Daniels, Gregory, McDermott, David
Publicado no J Immunother Cancer (2014)